$275 Million

SpringWorks Therapeutics, Inc.

Follow-on Offering

Bookrunner, December 2023

SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics, Inc. (“SpringWorks” or the “Company”) is commercial-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. OGSIVEO™ (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment, is their first U.S. Food and Drug Administration, or FDA-approved therapy. The Company has a differentiated portfolio of small molecule targeted oncology product candidates and are advancing programs in both rare tumor types as well as highly prevalent, genetically defined cancers.